- Home
- Results news
- Advanced Enzyme Technologies
- Q2 FY27 results
Advanced Enzyme Technologies Q2 FY27 results: net profit up 14.4% to ₹51.15 crore, revenue up 16.2%
Advanced Enzyme Technologies Ltd reported consolidated revenue of ₹214.51 crore in Q2 FY27, up 16.2% from Q2 FY26. EBITDA rose 20.1% to ₹72.11 crore, while net profit increased 14.4% to ₹51.15 crore and basic EPS was ₹4.33. The quarter ended 30 September 2026 also recorded a sequential recovery in revenue, EBITDA and profit.
Key points
- Consolidated Q2 FY27 revenue was ₹214.51 crore, up 16.2% year on year and 13.0% from Q1 FY27.
- EBITDA was ₹72.11 crore, with a 33.6% margin, compared with ₹60.06 crore and a 32.5% margin in Q2 FY26.
- Net profit was ₹51.15 crore, up 14.4% from Q2 FY26 and 32.5% from Q1 FY27; basic EPS was ₹4.33.
- H1 FY27 revenue was ₹406.22 crore, up 9.7%, while net profit rose 5.4% to ₹89.74 crore.
- The stock closed 7.6% higher on the reaction day and was up 4.8% from the pre-results close by the next day’s close.
How did Advanced Enzyme Technologies perform in Q2 FY27?
Advanced Enzyme Technologies reported consolidated revenue of ₹214.51 crore in Q2 FY27, up ₹29.98 crore or 16.2% from ₹184.53 crore in Q2 FY26. EBITDA rose ₹12.05 crore or 20.1% to ₹72.11 crore, while the margin expanded 1.1 percentage points to 33.6%. Net profit increased ₹6.42 crore or 14.4% to ₹51.15 crore, and basic EPS was ₹4.33 against ₹3.87.
Against Q1 FY27, revenue increased ₹24.72 crore or 13.0% to ₹214.51 crore. EBITDA rose ₹21.15 crore or 41.5% to ₹72.11 crore and its margin expanded 6.7 percentage points to 33.6%. Net profit rose ₹12.56 crore or 32.5% to ₹51.15 crore, while basic EPS increased ₹1.02 to ₹4.33. The standalone basis showed revenue of ₹137.17 crore and profit after tax of ₹41.7 crore.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 214.51 | 189.79 | 184.53 | +16.2% | +13.0% |
| Other income | 8.72 | 13.02 | 10.28 | −15.2% | −33.0% |
| Total expenses | 154.47 | 149.28 | 135.27 | +14.2% | +3.5% |
| EBITDA | 72.11 | 50.96 | 60.06 | +20.1% | +41.5% |
| EBITDA margin | 33.6% | 26.9% | 32.5% | +1.1 pp | +6.7 pp |
| Profit before tax | 68.76 | 53.53 | 59.54 | +15.5% | +28.5% |
| Tax | 17.59 | 14.94 | 14.81 | +18.8% | +17.7% |
| Net profit | 51.15 | 38.59 | 44.73 | +14.4% | +32.5% |
| EPS (₹) | 4.33 | 3.31 | 3.87 | +11.9% | +30.8% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Advanced Enzyme Technologies' costs and profit?
Total expenses increased ₹19.20 crore or 14.2% to ₹154.47 crore from Q2 FY26. Cost of materials rose ₹10.35 crore or 21.2% to ₹59.09 crore, employee cost increased ₹1.08 crore or 2.7% to ₹40.45 crore, and other expenses increased ₹5 crore or 12.3% to ₹45.53 crore. Depreciation was ₹10.90 crore, up ₹0.82 crore or 8.1%, while finance costs rose ₹0.46 crore or 63.9% to ₹1.18 crore.
Other income fell ₹1.56 crore or 15.2% to ₹8.72 crore from ₹10.28 crore in Q2 FY26. Tax expense increased ₹2.78 crore or 18.8% to ₹17.59 crore. There was no exceptional item in either quarter. Profit before tax rose ₹9.22 crore or 15.5% to ₹68.76 crore, while the net profit margin declined 0.4 percentage points to 23.8%.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 59.09 | 48.74 | +10.35 | +21.2% |
| Employee cost | 40.45 | 39.37 | +1.08 | +2.7% |
| Finance costs | 1.18 | 0.72 | +0.46 | +63.9% |
| Depreciation | 10.90 | 10.08 | +0.82 | +8.1% |
| Other expenses | 45.53 | 40.53 | +5 | +12.3% |
| Total expenses | 154.47 | 135.27 | +19.20 | +14.2% |
| Other income | 8.72 | 10.28 | −1.56 | −15.2% |
| Tax | 17.59 | 14.81 | +2.78 | +18.8% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
In H1 FY27, consolidated revenue was ₹406.22 crore, up ₹35.78 crore or 9.7% from ₹370.44 crore in H1 FY26. Total income rose ₹36.46 crore or 9.4% to ₹426.04 crore, while profit before tax increased ₹7.84 crore or 6.9% to ₹122.28 crore. Net profit rose ₹4.57 crore or 5.4% to ₹89.74 crore, and EPS was ₹7.64 against ₹7.44.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 406.22 | 370.44 | +9.7% |
| Profit before tax | 122.28 | 114.44 | +6.9% |
| Net profit | 89.74 | 85.17 | +5.4% |
| EPS (₹) | 7.64 | 7.44 | +2.7% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹1905.73 crore against ₹1838.76 crore at 31 March 2026, while total equity rose to ₹1719.89 crore from ₹1683.12 crore. Borrowings increased to ₹21.75 crore from ₹20.53 crore and cash to ₹158.76 crore from ₹108.75 crore. Inventories were ₹202.71 crore, trade receivables ₹138.03 crore and trade payables ₹44.85 crore.
H1 FY27 operating cash flow was ₹77.2 crore, compared with ₹64.71 crore in H1 FY26. Investing cash flow was ₹44.25 crore against an outflow of ₹30.73 crore, while financing cash flow was an outflow of ₹72.31 crore against an outflow of ₹65.28 crore. Capital expenditure was ₹51.6 crore, up from ₹18.34 crore.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 1,906 | 1,839 |
| Total equity | 1,720 | 1,683 |
| Borrowings | 21.75 | 20.53 |
| Cash and equivalents | 158.76 | 108.75 |
| Inventories | 202.71 | 177.28 |
| Trade receivables | 138.03 | 145.02 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 77.20 | 64.71 |
| Cash from investing | 44.25 | −30.73 |
| Cash from financing | −72.31 | −65.28 |
| Capital expenditure | 51.60 | 18.34 |
Source: Company's results filing (XBRL).
How has Advanced Enzyme Technologies done over the last 8 quarters?
Revenue reached its highest level of the listed eight quarters in Q2 FY27 at ₹214.51 crore, while profit and the EBITDA margin also peaked at ₹51.15 crore and 33.6%. The preceding low was Q4 FY25, when revenue was ₹167.18 crore and profit was ₹26.73 crore. From Q1 FY27, revenue rose from ₹189.79 crore and profit from ₹38.59 crore, reversing the decline in the EBITDA margin from 26.9%.
Revenue rose year on year in each of the last eight quarters. Over the listed period, the shape was uneven: revenue fell to ₹167.18 crore in Q4 FY25 before recovering, while the EBITDA margin moved from 32.7% in Q3 FY25 to 26.9% in Q1 FY27 and then increased to 33.6% in Q2 FY27.
What else did the company announce?
The Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. It also analysed requests from promoter-group members for reclassification from the promoter category to the public category. The company had earlier announced a buyback of up to 9.99% of paid-up equity capital and free reserves based on standalone audited financial statements, subject to the lower statutory limit.
The Buyback Committee closed the buyback with effect from the end of market hours on 30 October 2026. The company had bought 2,410,906 fully paid-up equity shares at an average price of ₹289.09 per share and used ₹696,962,962.22, or 99.99% of the maximum buyback size excluding transaction costs. It had extinguished 1,713,324 shares and said the remaining 697,582 would be extinguished within the prescribed timelines.
What did Advanced Enzyme Technologies' management say?
Management said Industrial Bio-processing and Animal Nutrition led growth in H1 FY27, while Human Nutrition was essentially flat. It also identified Human Nutrition as around 60% of sales, Non-Food revenue within Industrial Bio-processing down 7% YTD in H1 FY27 to ₹103 million, Europe revenue down 10% YoY in Q2 FY27 to ₹104 million, and H1 EBITDA and PAT growth trailing revenue growth as risks.
Management said it would bring newer animal-nutrition products to market through trials, studies and registrations, expand sales coverage and appoint distributors overseas, and develop target-specific bio-catalysis solutions for API manufacturers. It also plans to introduce more probiotics for human immunity, active health, gut health, nutraceutical and animal-feed applications, expand Baking Solutions in Europe, the Americas and Rest of World, and pursue geographic, inorganic and R&D growth.
How did Advanced Enzyme Technologies shares react?
After the filing appeared after market hours, the stock moved down 1.1% within five minutes, then rose 2.0% after 15 minutes and 3.0% after 30 minutes. It closed 7.6% above the previous close on the reaction day. The Biotechnology industry median rose 0.9%, so Advanced Enzyme Technologies exceeded the sector by 6.7 percentage points, while the Nifty Microcap 250 rose 1.4%.
By the next day’s close, the stock was up 4.8% from its pre-results close, compared with a 3.3% gain for the industry median and an excess-sector move of 1.6 percentage points. Earlier results-day reactions included gains of 2.2% on 1 August 2026 and 7.8% on 9 May 2026, and falls of 10.6% on 31 January 2026, 8.7% on 2 August 2025 and 12.7% on 9 November 2024.
| After the filing | Stock | Biotechnology median |
|---|---|---|
| 5 minutes | −1.1% | |
| 15 minutes | +2.0% | |
| 30 minutes | +3.0% | |
| Reaction day | +7.6% | +0.9% |
| Next day | +4.8% | +3.3% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 1 August 2026 | +2.2% |
| 9 May 2026 | +7.8% |
| 31 January 2026 | −10.6% |
| 12 November 2025 | +7.9% |
| 2 August 2025 | −8.7% |
| 13 May 2025 | −2.5% |
| 8 February 2025 | −2.4% |
| 9 November 2024 | −12.7% |
Source: MarketPing price-reaction measurement.
Quick answers
What was Advanced Enzyme Technologies' revenue in Q2 FY27?
Revenue from operations was ₹214.51 crore, up 16.2% from ₹184.53 crore in Q2 FY26 (consolidated).
Did Advanced Enzyme Technologies make a profit in Q2 FY27?
Yes. Net profit was ₹51.15 crore, against a net profit of ₹44.73 crore in Q2 FY26.
What was Advanced Enzyme Technologies' EPS in Q2 FY27?
Basic earnings per share were ₹4.33, against ₹3.87 in Q2 FY26.
How did Advanced Enzyme Technologies shares react to the Q2 FY27 results?
On the reaction day the stock moved +7.6% from the previous close; the median Biotechnology stock moved +0.9%.
When did Advanced Enzyme Technologies announce its Q2 FY27 results?
On 31 October 2026, in a filing to the NSE.
Sources
- Board Meeting Intimation for The Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 (BSE, 23 October 2026) · PDF
- Outcome of Board Meeting (NSE, 31 October 2026) · PDF
- Outcome of Board Meeting (NSE, 31 October 2026) · PDF
- The investor presentation (31 October 2026)
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.